Carl Gregory
Texas A&M University-College Station, TX·Medicine & Clinical Research
Osteosarcoma, the most common cancer that starts in bone, accounts for about 9% of childhood cancer deaths. Patients do worst when the tumor destroys bone, resists drugs or spreads to other organs (metastasis).
- Fields
Medicine & Clinical Research
Pharmacology
Biology
- Topics
osteosarcoma
bone cancer
pediatric cancer
- Grants
- 1 known grant, through Dec 2026
What they work on
- Measure how cDkkMo, a dog-specific antisense morpholino that blocks production of the Wnt-inhibitor protein Dkk-1, affects growth, survival and stress resistance of canine osteosarcoma cell lines and canine patient-derived xenografts.
- Compare the molecular mechanisms by which Dkk-1 drives bone destruction, tumor growth and cell survival in canine osteosarcoma cells with existing data on human osteosarcoma.
- Test whether cDkkMo, alone or combined with the chemotherapy drug cisplatin, slows tumor growth, lung metastases and bone destruction in mice carrying canine osteosarcoma from cell lines and patient-derived xenografts.
- Generate and characterize new canine osteosarcoma cell lines and patient-derived xenograft specimens and distribute them to other researchers studying the comparative biology of the disease.
More about the research
Current treatments do not target all three of these problems together. Dogs develop osteosarcoma often, and the dog disease closely resembles the human one in its pathology, genetics, causes, survival rates and standard treatments. That makes pet dogs with osteosarcoma a promising step toward testing new human therapies.
Why it matters
This work could lead to a new therapy for osteosarcoma, and potentially other malignant bone diseases, by blocking a tumor signal tied to bone destruction, tumor growth and metastasis. If testing in dogs proves to be a sound step toward human trials, the work could eventually help reduce illness and death from osteosarcoma, especially among children.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Amer Najjar
University of Texas MD Anderson Cancer Center, TX·Medicine & Clinical Research
Profile CD24 glycosylation patterns in osteosarcoma cells to identify tumor-specific sugar-modified sites (epitopes) that a therapeutic antibody could selectively target.
Jason Yustein
Emory University, GA·Medicine & Clinical Research
Map single-cell protein and RNA signatures and cell-cell communication in MYC-amplified human and mouse osteosarcoma, using patient-derived xenografts and engineered mice, and disrupt candidate metastasis-linked signals genetically.
Seth Pollack
Northwestern University, IL·Medicine & Clinical Research
Determine a safe and effective dose of B10G5, an antibody that neutralizes the tumor-shed immune-suppressing protein MIC, and test whether it activates NK cells within canine soft tissue sarcomas.
The school
Texas A&M University-College Station: 23 labs on PI Pages, $1.4B a year on research, 768 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.